Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2010-02-01 (16 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PARIS (75011), Paris
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL GRANDE PHARMACIE : revenue, balance sheet and financial ratios
SELARL GRANDE PHARMACIE is a French company
founded 16 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PARIS (75011),
this company of category PME
shows in 2024 a net income positive of 2 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL GRANDE PHARMACIE (SIREN 519458434)
Indicator
2024
2023
2021
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
2 370 €
18 349 €
178 469 €
43 044 €
46 364 €
32 272 €
58 968 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELARL GRANDE PHARMACIE generates positive net income of 2 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 59 k€ -> 2 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
2 370 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 80%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 52%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
80.315%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
51.88%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL GRANDE PHARMACIE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2021
2023
2024
Debt ratio
230.219
200.027
167.971
144.77
119.762
87.774
80.315
Financial autonomy
27.562
30.784
34.545
36.719
40.079
49.675
51.88
Repayment capacity
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
80.312024
2021
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average
In 2024, the debt ratio of SELARL GRANDE PHARMACIE (80.31) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
51.88%2024
2021
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good+8 pts over 3 years
In 2024, the financial autonomy of SELARL GRANDE PHARMACIE (51.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 429.39. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
429.393
Liquidity indicators evolution SELARL GRANDE PHARMACIE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2021
2023
2024
Liquidity ratio
233.531
232.466
261.241
223.109
271.065
450.744
429.393
Interest coverage
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
429.392024
2021
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Excellent
In 2024, the liquidity ratio of SELARL GRANDE PHARMACIE (429.39) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Positioning of SELARL GRANDE PHARMACIE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL GRANDE PHARMACIE is estimated at
33 086 €
(range 23 041€ - 49 499€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
23k€33k€49k€
33 086 €Range: 23 041€ - 49 499€
NAF 5 année 2024
Valuation method used
Net Income Multiple
2 370 €
×
14.0x
=33 087 €
Range: 23 041€ - 49 500€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL GRANDE PHARMACIE with other companies in the same sector:
Frequently asked questions about SELARL GRANDE PHARMACIE
What is the revenue of SELARL GRANDE PHARMACIE ?
The revenue of SELARL GRANDE PHARMACIE is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL GRANDE PHARMACIE profitable?
Yes, SELARL GRANDE PHARMACIE generated a net profit of 2 k€ in 2024.
Where is the headquarters of SELARL GRANDE PHARMACIE ?
The headquarters of SELARL GRANDE PHARMACIE is located in PARIS (75011), in the department Paris.
Where to find the tax return of SELARL GRANDE PHARMACIE ?
The tax return of SELARL GRANDE PHARMACIE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL GRANDE PHARMACIE operate?
SELARL GRANDE PHARMACIE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart